A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

September 26, 2023

Study Completion Date

September 26, 2023

Conditions
Psoriasis
Interventions
DRUG

Guselkumab

Guselkumab 100 mg will be administered as a SC injection.

DRUG

Placebo

Matching placebo will be administered as a SC injection.

Trial Locations (26)

100191

Peking University Third Hospital, Beijing

100730

Beijing Tongren Hospital, CMU, Beijing

200025

Shanghai Ruijin Hospital, Shanghai

200040

Huashan Hospital Fudan University, Shanghai

200050

Shanghai skin disease hospital, Shanghai

210029

Jiangsu Province Hospital, Nanjing

210042

Hospital of Dermatology, Chinese Academy of Medical Science, Nanjing

230022

The 1st affiliated hospital of Anhui Medical University, Hefei

250022

Skin Disease Hospital of Shandong Province, Jinan

300052

Tianjin Medical University General Hospital, Tianjin

300120

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin

310004

Zhejiang Provincial People's Hospital, Hangzhou

310009

The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou

310016

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

350005

Fujian Medical University, Fuzhou

400016

The First Affiliated Hospital of Chongqing Medical University, Chongqing

400038

The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing

410008

Xiangya Hospital Central South University, Changsha

410011

The second Xiangya Hospital of Central South University, Changsha

430022

Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan

450003

Henan province people's hospital, Zhengzhou

510091

Dermatology Hospital of Southern Medical University, Guangzhou

518053

University of Hong Kong-Shenzhen Hospital, Shenzhen

610041

West China Hospital,Sichuan University, Chengdu

710004

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04914429 - A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter